Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Colorectal Neoplasms

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 100 articles: HTML format

Single Articles

November 2025
1. HARAGUCHI E, Akiyoshi T, Noguchi T, Sakamoto T, et al
   Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer.
   Int J Cancer. 2025;157:2146-2155.
   PubMed     Abstract available
   
   
   
2. HORESH N, Dourado J, Rogers P, Aeschbacher P, et al
   Fragility Index analysis for robustness of evidence in Randomized Controlled Trials in National Comprehensive Cancer Network (NCCN) guidelines for rectal cancer.
   Int J Cancer. 2025;157:1864-1875.
   PubMed     Abstract available
   
   
   September 2025
3. VAN LANEN AS, Kok DE, Wesselink E, Derksen JWG, et al
   Pre- and post-diagnostic meat intake in relation to risk of recurrence and mortality among individuals with stage I-III colorectal cancer.
   Int J Cancer. 2025 Sep 18. doi: 10.1002/ijc.70113.
   PubMed     Abstract available
   
   
   
4. DOMINGUEZ-ROVIRA X, Arnau-Collell C, Gonfaus-Ortiz G, Llargues-Sistac G, et al
   Germline pathogenic variants in HIC1 DNA binding domains are associated with familial serrated polyposis syndrome.
   Int J Cancer. 2025;157:1154-1167.
   PubMed     Abstract available
   
   
   
5. POTTHOFF K, Uhlig J, Jacobasch L, Muller L, et al
   Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VA
   Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70139.
   PubMed     Abstract available
   
   
   
6. LI C
   Comments on "Early-life anthropometry and colorectal cancer risk in adulthood: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis of prospective studies".
   Int J Cancer. 2025 Sep 2. doi: 10.1002/ijc.70131.
   PubMed    
   
   
   
7. BRITO-ROCHA T, Constancio V, Leite-Silva P, Carvalho-Maia C, et al
   Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.
   Int J Cancer. 2025;157:1006-1019.
   PubMed     Abstract available
   
   
   August 2025
8. RAJTMAJEROVA M, Ambrozkiewicz F, Hlavac V, Trailin A, et al
   Genetic differences between primary colorectal cancer and its paired synchronous and metachronous metastases.
   Int J Cancer. 2025 Aug 30. doi: 10.1002/ijc.70116.
   PubMed     Abstract available
   
   
   
9. PHAM TT, Nimptsch K, Aleksandrova K, Jenab M, et al
   Circulating fatty acid binding protein 4 (FABP-4) concentrations and mortality in individuals with colorectal cancer in the European Prospective Investigation into Cancer and Nutrition study.
   Int J Cancer. 2025 Aug 26. doi: 10.1002/ijc.70090.
   PubMed     Abstract available
   
   
   
10. LI T, Li Y, Yin L, Li W, et al
    Folic acid fortification and late-onset colorectal cancer risk: A systematic assessment of the worldwide evidence.
    Int J Cancer. 2025 Aug 25. doi: 10.1002/ijc.70109.
    PubMed     Abstract available
    
    
    
11. YUAN T, Tagscherer KE, Roth W, Bewerunge-Hudler M, et al
    Methylation-based alcohol consumption scores as prognostic biomarkers in colorectal cancer: Insights from a population-based cohort.
    Int J Cancer. 2025 Aug 19. doi: 10.1002/ijc.70086.
    PubMed     Abstract available
    
    
    
12. PIRINI F, Calzari L, Tedaldi G, Tebaldi M, et al
    Comprehensive genetic and epigenetic characterization of Lynch-like syndrome patients.
    Int J Cancer. 2025;157:788-799.
    PubMed     Abstract available
    
    
    
13. LARSEN PT, Jorgensen SF, Rasmussen M, Andersen B, et al
    Screening outcomes at second FIT screening in individuals with a first time negative FIT-result or low-risk adenomas: Results from a nationwide FIT screening program.
    Int J Cancer. 2025;157:698-708.
    PubMed     Abstract available
    
    
    July 2025
14. BELLO-PEREZ M, Mascarell P, Fernandez-Gonzalez M, Garcia JA, et al
    ADAR1 mRNA quantification for predicting HSIL in persons with HIV and abnormal anal cytology.
    Int J Cancer. 2025 Jul 24. doi: 10.1002/ijc.70050.
    PubMed     Abstract available
    
    
    
15. TRIPATHI C, Tovar Perez JE, Kapoor S, Muhsin A, et al
    Antitumor efficacy of intermittent low-dose erlotinib plus sulindac via MHC upregulation and remodeling of the immune cell niche.
    Int J Cancer. 2025;157:355-370.
    PubMed     Abstract available
    
    
    
16. LINSSEN JDG, Schafrat PJM, de Back TR, van Erning FN, et al
    Predisposing conditions in patients with small intestinal adenocarcinomas in the Netherlands: A 20-year nationwide cohort study.
    Int J Cancer. 2025;157:218-231.
    PubMed     Abstract available
    
    
    
17. RUGGIERO R, Ottaiano A, Tathode M, Sirica R, et al
    Genetic variants linked to type 2 diabetes in CDKN1B and TCF7L2 influence survival outcomes in metastatic colorectal cancer.
    Int J Cancer. 2025 Jul 14. doi: 10.1002/ijc.70035.
    PubMed     Abstract available
    
    
    
18. VAN DER HAAR AVILA I, Zhang T, Lorrain V, Keuning E, et al
    Tumor desialylation surpasses anti-PD-L1 checkpoint therapy in restoring anti-tumor immunity in a murine model for colorectal cancer.
    Int J Cancer. 2025 Jul 7. doi: 10.1002/ijc.70031.
    PubMed     Abstract available
    
    
    
19. WIND KL, Steffensen JH, Jakobsen AV, Kronborg C, et al
    Prognostic significance of pre-treatment immune-inflammation biomarkers in anal cancer: A study combining real-world data and a meta-analysis.
    Int J Cancer. 2025;157:193-200.
    PubMed     Abstract available
    
    
    
20. MOLLER L, Szentkiralyi A, Eisfeld C, Wellmann I, et al
    Incidence trends and relative survival of colorectal neuroendocrine neoplasms: A population-based study using German cancer registry data.
    Int J Cancer. 2025;157:116-125.
    PubMed     Abstract available
    
    
    June 2025
21. CHAPLIN A, Rodriguez RM, Barcelo-Nicolau M, Perez-Romero K, et al
    Plasma fatty acids depletion: A metabolic signature related to colon cancer.
    Int J Cancer. 2025 Jun 23. doi: 10.1002/ijc.70015.
    PubMed     Abstract available
    
    
    
22. SERGEEV D, Heisser T, Hoffmeister M, Brenner H, et al
    Potential for enhancing efficacy of screening colonoscopy by lowering starting ages and extending screening intervals: A modelling study for Germany.
    Int J Cancer. 2025;156:2303-2310.
    PubMed     Abstract available
    
    
    
23. PASSEN CV, Krug J, Weiss L, Abdou MM, et al
    Integrin beta6 expression in colorectal cancer cells promotes liver metastasis through enhanced adhesion to endothelial fibronectin.
    Int J Cancer. 2025 Jun 9. doi: 10.1002/ijc.35504.
    PubMed     Abstract available
    
    
    
24. KORSGAARD U, Kristensen MP, Garcia-Rodriguez JL, Kjaer-Frifeldt S, et al
    The prognostic potential of RNA in stage II colon cancer: Insights from a screened multicenter population-based cohort study.
    Int J Cancer. 2025 Jun 6. doi: 10.1002/ijc.35507.
    PubMed     Abstract available
    
    
    May 2025
25. VAN ZUTPHEN M, Verkaar AJCF, van Duijnhoven FJB, Voortman T, et al
    Early-life anthropometry and colorectal cancer risk in adulthood: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis of prospective studies.
    Int J Cancer. 2025 May 28. doi: 10.1002/ijc.35461.
    PubMed     Abstract available
    
    
    
26. STERPETTI G, Sterpetti AV
    Increased mortality from colorectal cancer in younger individuals: The preventive role of aspirin and statins.
    Int J Cancer. 2025 May 27. doi: 10.1002/ijc.35495.
    PubMed    
    
    
    April 2025
27. HOANG T, Choi MK, Oh JH, Kim J, et al
    Utility of circulating tumor DNA to detect minimal residual disease in colorectal cancer: A systematic review and network meta-analysis.
    Int J Cancer. 2025 Apr 28. doi: 10.1002/ijc.35442.
    PubMed     Abstract available
    
    
    
28. ZHOU Y, Fu M, Guan X, Wang C, et al
    Targeted plasma lipidomic profiles associated with colorectal cancer risk and effect modifications by common risk factors and particulate matter exposure.
    Int J Cancer. 2025 Apr 21. doi: 10.1002/ijc.35449.
    PubMed     Abstract available
    
    
    
29. BLANKS RG, Alison RJ, Reeves GK
    Invitation for FOBt screening and colorectal cancer mortality: A prospective analysis in the Million Women Study cohort.
    Int J Cancer. 2025 Apr 11. doi: 10.1002/ijc.35437.
    PubMed     Abstract available
    
    
    
30. GE X, Feng Y, Tan S, Mao W, et al
    Gestational colorectal cancer: Mechanisms, treatments, and prognosis.
    Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35425.
    PubMed     Abstract available
    
    
    March 2025
31. JOHANNSEN IR, Boysen AK, Mortensen FV, Kirkegard J, et al
    Temporal trends in incidence and mortality of colorectal cancer in Denmark from 2007 to 2022.
    Int J Cancer. 2025 Mar 14. doi: 10.1002/ijc.35400.
    PubMed     Abstract available
    
    
    
32. VAN NASSAU SCMW, Zwart K, van der Baan FH, Vink GR, et al
    Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort.
    Int J Cancer. 2025 Mar 13. doi: 10.1002/ijc.35410.
    PubMed     Abstract available
    
    
    
33. DROSDOWSKY A, Lamb KE, Te Marvelde L, Gibbs P, et al
    Factors associated with diagnostic and treatment intervals in colorectal cancer: A linked data study.
    Int J Cancer. 2025 Mar 13. doi: 10.1002/ijc.35414.
    PubMed     Abstract available
    
    
    
34. KATSARA MA, van den Berg D, Spaander MCW, van Vuuren AJ, et al
    The impact of extended invitation intervals on stage distribution of screen-detected and interval cancer within the Dutch colorectal cancer screening program.
    Int J Cancer. 2025 Mar 13. doi: 10.1002/ijc.35371.
    PubMed     Abstract available
    
    
    February 2025
35. ZHANG Y, Song K, Zhou Y, Chen Y, et al
    Accuracy and long-term effectiveness of established screening modalities and strategies in colorectal cancer screening: An umbrella review.
    Int J Cancer. 2025 Feb 25. doi: 10.1002/ijc.35381.
    PubMed     Abstract available
    
    
    
36. GALANOS LJK, Rijken A, Elferink MAG, Kok NFM, et al
    Influence of a nationwide colorectal cancer screening program on the incidence of synchronous colorectal peritoneal metastases.
    Int J Cancer. 2025 Feb 17. doi: 10.1002/ijc.35356.
    PubMed     Abstract available
    
    
    
37. PEREMIQUEL-TRILLAS P, Martinez JM, Paytubi S, Frias-Gomez J, et al
    Acceptability and somatic mutations in cervicovaginal self-sampling for early endometrial cancer detection in women with Lynch syndrome.
    Int J Cancer. 2025 Feb 14. doi: 10.1002/ijc.35368.
    PubMed     Abstract available
    
    
    
38. AL NAHAS A, Yammine Ghantous S, Morales Berstein F, Cakmak EK, et al
    Associations between degree of food processing and colorectal cancer risk in a large-scale European cohort.
    Int J Cancer. 2025 Feb 8. doi: 10.1002/ijc.35361.
    PubMed     Abstract available
    
    
    
39. JIN F, Poynten IM, Hillman RJ, Law C, et al
    Does use of anal cytology as a triage test improve the performance of high-risk human papillomavirus screening in gay and bisexual men for anal cancer prevention?
    Int J Cancer. 2025;156:575-586.
    PubMed     Abstract available
    
    
    January 2025
40. BYRD DA, Damerell V, Gomez Morales MF, Hogue SR, et al
    The gut microbiome is associated with disease-free survival in stage I-III colorectal cancer patients.
    Int J Cancer. 2025 Jan 31. doi: 10.1002/ijc.35342.
    PubMed     Abstract available
    
    
    
41. AKKUS E, Karaoglan BB, Kayaalp M, Turmus U, et al
    Stage-specific characterization of "early-onset colorectal cancer": Localized and synchronous metastatic disease.
    Int J Cancer. 2025 Jan 30. doi: 10.1002/ijc.35336.
    PubMed     Abstract available
    
    
    
42. HU X, Xie S, Yang Z, Zhao X, et al
    Aggressive characteristics of tumor deposits in colorectal cancer highlight the need for staging refinement in patients with 0-3 metastatic lymph nodes.
    Int J Cancer. 2025 Jan 20. doi: 10.1002/ijc.35306.
    PubMed     Abstract available
    
    
    
43. OGUZ ERDOGAN AS, Simmer F, Nagtegaal ID
    Tumor deposits should not be placed in the M category of TNM: A comparative survival analysis using SEER data.
    Int J Cancer. 2025;156:274-279.
    PubMed     Abstract available
    
    
    
44. DYER CEF, Jin F, Hillman RJ, Nyitray AG, et al
    Self-collected versus clinician-collected anal swabs for anal cancer screening: A systematic review and meta-analysis.
    Int J Cancer. 2025;156:79-90.
    PubMed     Abstract available
    
    
    December 2024
45. ADAMS J, Stebbing J
    Effects of MCL-1 expression in colorectal cancer.
    Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35308.
    PubMed    
    
    
    
46. MITTAL P, Battaglin F, Baca Y, Xiu J, et al
    Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes.
    Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35304.
    PubMed     Abstract available
    
    
    
47. VAN STIGT BJ, Lansdorp-Vogelaar I, Spaander MCW, van Vuuren AJ, et al
    Interval cancer risk after the upper age limit of screening has been reached: Informing risk stratification in FIT-based colorectal cancer screening.
    Int J Cancer. 2024 Dec 19. doi: 10.1002/ijc.35294.
    PubMed     Abstract available
    
    
    
48. HUNG FH, Peng HP, Hung CF, Hsieh LL, et al
    Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan.
    Int J Cancer. 2024;155:2201-2210.
    PubMed     Abstract available
    
    
    
49. SONG Y, Ren S, Wu S, Liu W, et al
    Glucocorticoid promotes metastasis of colorectal cancer via co-regulation of glucocorticoid receptor and TET2.
    Int J Cancer. 2024 Dec 11. doi: 10.1002/ijc.35285.
    PubMed     Abstract available
    
    
    
50. FORSTI A, Ambrozkiewicz F, Marciniak M, Lubinski J, et al
    Search for germline gene variants in colorectal cancer families presenting with multiple primary colorectal cancers.
    Int J Cancer. 2024 Dec 10. doi: 10.1002/ijc.35283.
    PubMed     Abstract available
    
    
    
51. CAI R, Ke L, Zhao Y, Zhao J, et al
    NMR-based metabolomics combined with metabolic pathway analysis reveals metabolic heterogeneity of colorectal cancer tissue at different anatomical locations and stages.
    Int J Cancer. 2024 Dec 4. doi: 10.1002/ijc.35273.
    PubMed     Abstract available
    
    
    November 2024
52. SHAHRIVAR M, Dietrich CE, Glimelius B, Saraste D, et al
    Type II diabetes and metformin use does not affect colorectal cancer prognosis.
    Int J Cancer. 2024 Nov 27. doi: 10.1002/ijc.35266.
    PubMed     Abstract available
    
    
    
53. LU SSM, Rutegard M, Haggstrom C, Gylfe A, et al
    Prior antibiotics exposure is associated with an elevated risk of surgical site infections, including anastomotic leakage, after colon cancer but not rectal cancer surgery: A register-based study of 38,839 patients.
    Int J Cancer. 2024 Nov 27. doi: 10.1002/ijc.35269.
    PubMed     Abstract available
    
    
    
54. FENG X, Yao Q, Xu Y, Zhang J, et al
    Approaches for Lynch syndrome screening and characteristics of subtypes with mismatch repair deficiency in patients with colorectal carcinoma.
    Int J Cancer. 2024;155:1780-1791.
    PubMed     Abstract available
    
    
    
55. REICHMANN R, Nimptsch K, Pischon T, Gunter MJ, et al
    Sex- and site-specific associations of circulating lipocalin 2 and incident colorectal cancer: Results from the EPIC cohort.
    Int J Cancer. 2024 Nov 7. doi: 10.1002/ijc.35205.
    PubMed     Abstract available
    
    
    
56. TRAILIN A, Ali E, Ye W, Pavlov S, et al
    Prognostic assessment of T-cells in primary colorectal cancer and paired synchronous or metachronous liver metastasis.
    Int J Cancer. 2024 Nov 7. doi: 10.1002/ijc.35252.
    PubMed     Abstract available
    
    
    
57. SCHEI-ANDERSEN AJ, Hendricks LAJ, van der Post RS, Mensenkamp AR, et al
    Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single-center study.
    Int J Cancer. 2024;155:1567-1576.
    PubMed     Abstract available
    
    
    October 2024
58. SONG CH, Kim N, Nam RH, Choi SI, et al
    Ninjurin1 deficiency differentially mitigates colorectal cancer induced by azoxymethane and dextran sulfate sodium in male and female mice.
    Int J Cancer. 2024 Oct 17. doi: 10.1002/ijc.35225.
    PubMed     Abstract available
    
    
    September 2024
59. DAMERELL V, Klaassen-Dekker N, Brezina S, Ose J, et al
    Circulating tryptophan-kynurenine pathway metabolites are associated with all-cause mortality among patients with stage I-III colorectal cancer.
    Int J Cancer. 2024 Sep 23. doi: 10.1002/ijc.35183.
    PubMed     Abstract available
    
    
    
60. 
    Correction to "Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)".
    Int J Cancer. 2024 Sep 18. doi: 10.1002/ijc.35186.
    PubMed    
    
    
    
61. 
    Expression of Concern: The retinoblastoma protein interacts with Bag-1 in human colonic adenoma and carcinoma derived cell lines.
    Int J Cancer. 2024;155:E9.
    PubMed    
    
    
    
62. NG L, Sin RW, Cheung DH, Wong CK, et al
    Identification and evaluation of a serum microRNA panel to diagnose colorectal cancer patients.
    Int J Cancer. 2024 Sep 8. doi: 10.1002/ijc.35175.
    PubMed     Abstract available
    
    
    
63. LONARE A, Raychaudhuri K, Shah S, Madhu G, et al
    14-3-3sigma restricts YY1 to the cytoplasm, promoting therapy resistance, and tumor progression in colorectal cancer.
    Int J Cancer. 2024 Sep 6. doi: 10.1002/ijc.35176.
    PubMed     Abstract available
    
    
    
64. NESIC M, Rasmussen MH, Henriksen TV, Demuth C, et al
    Beyond basics: Key mutation selection features for successful tumor-informed ctDNA detection.
    Int J Cancer. 2024;155:925-933.
    PubMed     Abstract available
    
    
    August 2024
65. STERPETTI AV, Borrelli V, Sapienza P, Campagnol M, et al
    Comments on "Differences in survival and recurrence of colorectal cancer by stage across population-based European registries".
    Int J Cancer. 2024 Aug 27. doi: 10.1002/ijc.35150.
    PubMed    
    
    
    
66. NAKATSUMI H, Komatsu Y, Harada K, Kawamoto Y, et al
    A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801.
    Int J Cancer. 2024 Aug 14. doi: 10.1002/ijc.35116.
    PubMed     Abstract available
    
    
    
67. VAN DE WEERD S, Torang A, van den Berg I, Lammers V, et al
    Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer.
    Int J Cancer. 2024 Aug 8. doi: 10.1002/ijc.35120.
    PubMed     Abstract available
    
    
    July 2024
68. LI J, Roshelli Baker J, Aglago EK, Zhao Z, et al
    Pre-diagnostic plasma advanced glycation end-products and soluble receptor for advanced glycation end-products and mortality in colorectal cancer patients.
    Int J Cancer. 2024 Jul 26. doi: 10.1002/ijc.35114.
    PubMed     Abstract available
    
    
    
69. LU L, Zhang Q, Aladelokun O, Berardi D, et al
    Asparagine synthetase and G-protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer.
    Int J Cancer. 2024 Jul 22. doi: 10.1002/ijc.35104.
    PubMed     Abstract available
    
    
    
70. WEI TT, Blanc E, Peidli S, Bischoff P, et al
    High-confidence calling of normal epithelial cells allows identification of a novel stem-like cell state in the colorectal cancer microenvironment.
    Int J Cancer. 2024 Jul 19. doi: 10.1002/ijc.35079.
    PubMed     Abstract available
    
    
    
71. DANKNER R, Chetrit A, Avraham SB, Agay N, et al
    A historical cohort study with 27,754 individuals on the association between meat consumption and gastrointestinal tract and colorectal cancer incidence.
    Int J Cancer. 2024 Jul 19. doi: 10.1002/ijc.35084.
    PubMed     Abstract available
    
    
    
72. RAFIQUE A, Ali I, Kim S, Farooq A, et al
    Toll-like receptor 13-mediated signaling protects against the development of colon cancer.
    Int J Cancer. 2024 Jul 11. doi: 10.1002/ijc.35089.
    PubMed     Abstract available
    
    
    
73. NISHIHARA K, Nakano S, Yamaji T, Goto A, et al
    Height, body mass index, physical activity, and risk of colorectal cancer in relation to expression of insulin receptor: The Japan Public Health Center-based Prospective Study.
    Int J Cancer. 2024 Jul 6. doi: 10.1002/ijc.35075.
    PubMed     Abstract available
    
    
    
74. HAMMARSTROM K, Nunes L, Mathot L, Mezheyeuski A, et al
    Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer.
    Int J Cancer. 2024;155:40-53.
    PubMed     Abstract available
    
    
    May 2024
75. HOLTHUIJSEN DDB, van Roekel EH, Bours MJL, Ueland PM, et al
    Longitudinal associations of plasma kynurenines and ratios with fatigue and quality of life in colorectal cancer survivors up to 12 months post-treatment.
    Int J Cancer. 2024 May 23. doi: 10.1002/ijc.34992.
    PubMed     Abstract available
    
    
    
76. WANG R, Lv C, Li D, Song Y, et al
    EEF1D stabilized by SRSF9 promotes colorectal cancer via enhancing the proliferation and metastasis.
    Int J Cancer. 2024 May 21. doi: 10.1002/ijc.35039.
    PubMed     Abstract available
    
    
    
77. HU M, Luo R, Yang K, Yu Y, et al
    Genomic landscape defines peritoneal metastatic pattern and related target of peritoneal metastasis in colorectal cancer.
    Int J Cancer. 2024 May 13. doi: 10.1002/ijc.35005.
    PubMed     Abstract available
    
    
    
78. WANG P, Song M, Eliassen AH, Wang M, et al
    Identifying modifiable risk factors to prevent aggressive colorectal cancer.
    Int J Cancer. 2024 May 8. doi: 10.1002/ijc.34993.
    PubMed     Abstract available
    
    
    
79. VAN LANEN AS, Kok DE, Wesselink E, Derksen JWG, et al
    Associations between low- and high-fat dairy intake and recurrence risk in people with stage I-III colorectal cancer differ by sex and primary tumour location.
    Int J Cancer. 2024 May 3. doi: 10.1002/ijc.34959.
    PubMed     Abstract available
    
    
    
80. HO VKY, Deijen CL, Hemmes B, van Erning FN, et al
    Trends in epidemiology and primary treatment of anal squamous cell carcinoma in the Netherlands (1990-2021).
    Int J Cancer. 2024;154:1569-1578.
    PubMed     Abstract available
    
    
    
81. BECERRA-TOMAS N, Markozannes G, Cariolou M, Balducci K, et al
    Post-diagnosis adiposity and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.
    Int J Cancer. 2024 May 1. doi: 10.1002/ijc.34905.
    PubMed     Abstract available
    
    
    
82. MARKOZANNES G, Becerra-Tomas N, Cariolou M, Balducci K, et al
    Post-diagnosis physical activity and sedentary behaviour and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.
    Int J Cancer. 2024 May 1. doi: 10.1002/ijc.34903.
    PubMed     Abstract available
    
    
    
83. CHAN DSM, Cariolou M, Markozannes G, Balducci K, et al
    Post-diagnosis dietary factors, supplement use and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.
    Int J Cancer. 2024 May 1. doi: 10.1002/ijc.34906.
    PubMed     Abstract available
    
    
    
84. TSILIDIS KK, Markozannes G, Becerra-Tomas N, Cariolou M, et al
    Post-diagnosis adiposity, physical activity, sedentary behaviour, dietary factors, supplement use and colorectal cancer prognosis: Global Cancer Update Programme (CUP Global) summary of evidence grading.
    Int J Cancer. 2024 May 1. doi: 10.1002/ijc.34904.
    PubMed     Abstract available
    
    
    April 2024
85. VASAVADA A, Stankiewicz Karita HC, Lin J, Schouten J, et al
    Methylation markers for anal cancer screening: A repeated cross-sectional analysis of people living with HIV, 2015-2016.
    Int J Cancer. 2024 Apr 29. doi: 10.1002/ijc.34977.
    PubMed     Abstract available
    
    
    
86. ZHANG Y, Win AK, Makalic E, Buchanan DD, et al
    Associations between pathological features and risk of metachronous colorectal cancer.
    Int J Cancer. 2024 Apr 27. doi: 10.1002/ijc.34979.
    PubMed     Abstract available
    
    
    
87. FU X, Huang J, Zhu J, Fan X, et al
    Prognosis and immunotherapy efficacy in dMMR&MSS colorectal cancer patients and an MSI status predicting model.
    Int J Cancer. 2024 Apr 9. doi: 10.1002/ijc.34946.
    PubMed     Abstract available
    
    
    
88. BOUVIER AM, Jooste V, Lillini R, Marcos-Gragera R, et al
    Differences in survival and recurrence of colorectal cancer by stage across population-based European registries.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34944.
    PubMed     Abstract available
    
    
    
89. SINGINI MG, Muchengeti M, Sitas F, Chen WC, et al
    Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34919.
    PubMed     Abstract available
    
    
    
90. MOEN L, Liu B, Bukirwa P, Chingonzoh T, et al
    Trends in the incidence of colorectal cancer in sub-Saharan Africa: A population-based registry study.
    Int J Cancer. 2024 Apr 3. doi: 10.1002/ijc.34942.
    PubMed     Abstract available
    
    
    
91. BRENNER H, Weber L, Cardoso R, Heisser T, et al
    Indications of sustained delay of colorectal cancer diagnoses in Germany during the first 2 years of the COVID-19 pandemic.
    Int J Cancer. 2024 Apr 1. doi: 10.1002/ijc.34943.
    PubMed    
    
    
    March 2024
92. LI YJ, Wang X, Wu YJ, Zhou XY, et al
    Access to colorectal cancer screening in populations in China, 2020: A coverage-focused synthesis analysis.
    Int J Cancer. 2024 Mar 30. doi: 10.1002/ijc.34938.
    PubMed     Abstract available
    
    
    
93. DOHERTY N, Cardwell C, Murchie P, Hill C, et al
    Use of 5-alpha reductase inhibitors and risk of gastrointestinal cancers in men with benign prostatic hyperplasia: A population-based cohort study.
    Int J Cancer. 2024 Mar 30. doi: 10.1002/ijc.34937.
    PubMed     Abstract available
    
    
    
94. TAN JY, Yeo YH, Ng WL, Fong ZV, et al
    How have US colorectal cancer mortality trends changed in the past 20 years?
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34926.
    PubMed     Abstract available
    
    
    
95. DAL MASO L, Toffolutti F, De Paoli A, Giudici F, et al
    Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population-based study in Italy.
    Int J Cancer. 2024 Mar 23. doi: 10.1002/ijc.34923.
    PubMed     Abstract available
    
    
    
96. ZNAOR A, Eser S, Bendahhou K, Shelpai W, et al
    Stage at diagnosis of colorectal cancer in the Middle East and Northern Africa: A population-based cancer registry study.
    Int J Cancer. 2024 Mar 8. doi: 10.1002/ijc.34895.
    PubMed     Abstract available
    
    
    
97. HORESH N, Emile SH, Garoufalia Z, Gefen R, et al
    Trends in management and outcomes of colon cancer in the United States over 15 years: Analysis of the National Cancer Database.
    Int J Cancer. 2024 Mar 7. doi: 10.1002/ijc.34910.
    PubMed     Abstract available
    
    
    
98. JEZIORSKI K
    Improving colon cancer screening in Poland. In search of the Holy Grail.
    Int J Cancer. 2024 Mar 4. doi: 10.1002/ijc.34909.
    PubMed    
    
    
    February 2024
99. LINDQUIST S, Frederiksen K, Petersen LK, Kjaer SK, et al
    The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
    Int J Cancer. 2024 Feb 28. doi: 10.1002/ijc.34896.
    PubMed     Abstract available
    
    
    January 2024
100. STIER EA, Clarke MA, Deshmukh AA, Wentzensen N, et al
     International Anal Neoplasia Society's consensus guidelines for anal cancer screening.
     Int J Cancer. 2024 Jan 31. doi: 10.1002/ijc.34850.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.